PET response-guided radiotherapy for advanced DLBCL?

摘要

In this issue of Blood, Freeman and colleagues report long-term outcomes in a large, population-based cohort of 723 patients with advanced diffuse large B-cell lymphoma (DLBCL) treated with 6 to 8 cycles of rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) and a consistent policy of end-of-therapy (EOT) positron emission tomography (PET)-guided radiotherapy (RT).(1) EOT PET-negative patients did not receive RT and had an 83% 3-year time to progression (TTP), with the authors suggesting such patients may reasonably be spared RT. A second key finding was that selected patients who received RT to nonprogressive, anatomically suitable EOT PET-positive sites had outcomes comparable to those in the PET-negative cohort.